BACKGROUND: Molecular testing to inform treatment and clinical trial choices is now the standard of care for several types of cancer. However, no established guidelines exist for the type of information physicians should cover during discussions with the patient about the test or its results. The objectives of this study were to identify physician and patient preferences regarding information and who should communicate this information and how to inform guidelines for these conversations. METHODS: Physicians and patients who participated in discussions regarding molecular testing were asked to choose 8 topics of most relevance out of a list of 18. The McNemar test was used to determine their top preferences. Patients were asked to identify what information they wanted to receive and who should inform them, and physicians were asked to identify the best aid to communication. RESULTS: Sixty-six patients identified 12 preferred topics: the benefits of testing (88%), how testing determines treatment (88%), implications for family (71%), whether a test indicates the seriousness of disease (68%), purpose of the test (64%), incidental findings (56%), explanation of cancer genetics (53%), how the test is done (46%), limitations (44%), explanation of biomarker (42%), risks (42%), and uninformative results (38%). Physicians added cost (59%). Patients preferred receiving information about molecular testing from their nurse or physician (85%), and physicians preferred using a pamphlet (67%) to augment communication. CONCLUSIONS: The topics identified as important to discuss can inform future guidelines and can contribute to effective communication regarding molecular testing. Cancer 2017;123:1610-6.
INTRODUCTION
Tumor molecular testing has led to a re-evaluation of oncologic paradigms in which mutations that occur in key oncogenic pathways and alter a cell's growth lead to cancerous tumors.
1,2 Molecular testing to identify targetable alterations for treatment is currently used to direct therapy in a variety of cancers, 3, 4 and the search for other treatable targets is being pursued rigorously. The National Cancer Institute basket trial MATCH, for example, uses molecular testing to match patients' tumor mutations to targeted treatments. 5 Guidelines exist to help direct discussions on germline genetic testing 6 ; however, with the exception of incidental findings (IFs) directives, there are no established guidelines for informational and results-oriented discussions about tumor molecular testing. [7] [8] [9] [10] [11] [12] [13] For example, in the recently updated American Society of Clinical Oncology (ASCO) guidelines for genetic and genomic testing for cancer susceptibility, 14 the discussion of somatic molecular testing focuses on the discovery of incidental hereditary findings. Guideline development committees usually consist of experts, physicians, stakeholders, and patient advocates. The National Comprehensive Cancer Network and ASCO recommend that panels include at least 1 patient and/or patient advocate. [15] [16] [17] However, multiple current patient opinions are not included. We believe the addition of patient voices in the creation of communication guidelines is important, because preferences can vary greatly among individuals, and the inclusion of multiple voices better expresses real patient preferences. In clinical observations, discrepancies have been identified between physician practice and patient preference for information. For example, although a majority of cancer patients report prognostic information as important and necessary, [18] [19] [20] [21] physicians frequently omit this information. 18, 22, 23 Existing patient and physician barriers to adequate communication exacerbate molecular testing communication gaps. For patients, inadequate health literacy and lack of understanding of complex genetic information make it difficult to fully understand molecular testing and results 24 and often lead to confusion between hereditary and somatic mutations. 25, 26 Misunderstandings about somatic testing can also contribute to patient concerns. 27 Barriers also exist on the physician's side, including a lack of clear understanding of tumor molecular testing 28, 29 resulting in difficulty determining which test to send and how to interpret results, 28, 30, 31 not providing the right amount and type of information for each patient, 4,17 difficulty translating technical concepts into lay language, [32] [33] [34] and difficulty assessing patient's understanding and information preferences. [35] [36] [37] [38] [39] Recognizing patient preferences is particularly difficult, because physicians expect patients to express their preferences 40 ; however, patients often do not speak up, and physicians do not readily recognize indirect expressions of concern. 41 The difficulty physicians have in knowing the amount and type of information to discuss 4, 17 and the well documented discordance between physician and patient information preferences in other areas, [18] [19] [20] [21] [22] [23] [42] [43] [44] [45] [46] combined with a lack of research on molecular testing communication, make it vital to include patients' voices in guideline development. Therefore, we conducted a study to identify patients' and physicians' top preferences for molecular testing information, and who and how this information is communicated, to inform future guidelines for tumor molecular testing discussions.
MATERIALS AND METHODS
Physicians who discuss molecular testing or results at Winship Cancer Institute (Winship) at Emory University Clifton Campus, St. Josephs', and John's Creek Hospitals were consented and then completed a short questionnaire. They were asked to contact the ethics team when a molecular testing conversation would occur. Upon this notification, the ethics team member offered the study to the patient who would be involved in the conversation. With consent, the conversation was observed and audio recorded. The patient completed a short questionnaire, either in person immediately after the conversation or by phone within 1 week.
Questionnaire Development
The patient questionnaire included a pick-list of 18 topics from which patients were instructed to choose the 8 topics they most wanted to be discussed. We, along with others, have successfully used this format in prior studies assessing informational preferences. 35, [47] [48] [49] Sixteen of the topics were adapted from the physician competencies for somatic testing outlined by the Inter-Society Coordinating Committee for Physician Education in Genomics. 50 These were reviewed by 3 physicians, and 3 topics (how the testing is done, who will do it, and what a biomarker is) were added. This draft was cognitively tested with 15 patients to determine whether the pick-list format was acceptable and if the simplified rephrasings of the competencies were clear. Minor editing was done, and 1 topic was eliminated as duplicative of topic 8 (implications for family). Patients also chose 2 preferred methods of receiving information about molecular testing from a list of 4 methods used at Winship in other settings: written information, short video, website, from physician/nurse, and 1 method suggested during cognitive testing: from another patient. The physician questionnaire included the picklist, from which physicians were asked to choose the 8 topics that were most important to communicate about molecular testing. It also included 1 question asking which 2 of 4 options used at Winship to assist in communication were most useful in this setting: 1) patient video, 2) pamphlet, 3) scripts for providers, and 4)website. The 18 pick-list topics covered 3 domains (see Table 1 ).
Quantitative Analysis
Descriptive statistics were generated for patient characteristics, including frequencies and percentages for categorical variables and means and standard deviations for numerical variables. The proportions of patients and physicians who selected each of 18 topics were reported. To determine which topics were most important to discuss, we identified optimal cutoff points between the first and 18th ranked topics using the maximum odds ratio derived from the McNemar test for comparing paired differences in proportions using the R package exact2x2 (R Foundation for Statistical Computing, Vienna, Austria). 51 Topics were ranked by the proportion of patients selecting each, testing the difference in proportions between topics 1 and 2 through topics 17 and 18 using the McNemar test. 52, 53 Also reported was the odds ratio, defined as P10/P01, where P10 is the proportion of patients selecting the higher ranked topic (topic 6, for example) but not the lower ranked topic (topic 7, for example), and P01 is the proportion of patients selecting the lower ranked topic (topic 7, for example) but not the higher ranked topic (topic 6, for example). At least 1 topic and at most 17 topics were to be included on the patient list. The Fisher exact test was used to determine whether there were significant differences between the preferences chosen by patients who were receiving results and those who were being introduced to molecular testing.
A similar analysis was performed to identify a cutoff point for physician-preferred topics. The proportion of patients selecting each topic was correlated with the proportion of physicians selecting each topic using the Pearson correlation coefficient. Chi-square or Fisher exact tests were used to compare preferred topics between the patient and physician groups. To identify cutoff points, significance was assessed at the .1 level; otherwise, significance was assessed at the .05 level. All tests performed were 2-sided, where applicable. The analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC) and R version 3.3.0 (R Foundation for Statistical Computing). Simple frequencies were calculated for the questions about how and by whom the information was communicated.
Power Analysis
Because we anticipated a small sample size of physicians, we conducted the power analysis for the patient population. Assuming a Type 1 error of 0.1 and a percentage discordant of 0.4 (P10 1 P01), we had 80% power to detect an odds ratio between 2 consecutive ranked topics of 3.0 with 66 patients. The same test had 97% power to detect an odds ratio of 5.0 with 66 patients.
RESULTS

Participants
Of 74 patients who were approached, 70 (95%) consented. Two conversations did not discuss tumor molecular testing, and 2 consented patients withdrew, for a final sample size of 66. Twenty-eight physicians participated, including: 6 (21%) community oncologists and 22 (79%) academic oncologists from the following specialties: breast (4 physicians; 18%); aerodigestive (6 physicians; 27%), melanoma (3 physicians; 14%), gastrointestinal (3 physicians; 14%), myeloma (5 physicians; 23%), and lymphoma (1 physician; 5%). Twenty-seven physicians (96%) completed the questionnaire, and clinic conversations were recorded with 19 physicians (68%).
The median patient age was 62 years, 46 (70%) were women, 44 (67%) were white, 39 (59%) were college 8 (12) 1 (4) a These items were on the combined patient/physician preference list. The patient/physician correlation was statistically significant (correlation coefficient, 0.71; 95% confidence interval, 0.37-0.88; P 5.001).
Original Article educated, and 32 (49%) earned a yearly wage $60,000 (Table 2) . Their types of cancers included lung cancer (20 patients; 30%), colorectal cancer (17 patients; 26%), breast cancer (12 patients; 18%), melanoma (6 patients; 9%), gastric cancer (4 patients; 6%), liver cancer (2 patients; 3%), and other cancers (5 patients; 8%). This was the first molecular testing for 44 patients; 22 of these conversations occurred before and 22 occurred after the testing. Twelve of the conversations discussed testing that had been done elsewhere and were reviews of what the patient had already been told. Of these, 5 conversations focused on results, and 7 focused on descriptions of the tests. Ten of the conversations discussed new expanded testing beyond the original standard-of-care testing to assess eligibility for clinical trials. In short, 27 conversations focused on return of results, and the remaining 39 focused on what molecular testing is, how it is done, and its implications.
Informational Preferences
Patients' top 2 preferred topics were the benefits of testing (88%) and how testing determines treatment (88%). Patients also chose 10 additional topics: implications for family (71%), whether the test indicates seriousness of disease (68%), test purpose (64%), incidental findings (56%), explanation of cancer genetics (53%), how the test is done (46%), limitations (44%), explanation of biomarker (42%), risks (42%), and an uninformative result (38%) (for statistical analyses, see Table 3 ). There were no significant differences between preferences chosen by patients who were and were not receiving results. Physicians' top choices were: how the test determines treatment (100%), test purpose (93%), and benefits (89%). Physicians also chose limitations (70%), explanation of biomarker (63%), cost (59%), how the test is done (56%), risks (56%), and prognostic information (52%) (for statistical analyses, see Table 4 ). The combined patient/physician list of 13 topics is indicated by superscript a in Table 1 and includes all of the patients' 12 topics plus cost. Statistically significant differences in the proportion of patients versus physicians selecting topics are summarized in Table 5 . a No odds ratios were significantly different than 1 (P >.1). The maximum odds ratio occurred between topics 2 and 4, and the next highest odds ratio occurred between topics 7 and 9 (odds ratio, 1.57). Cutoff points are denoted by lines.
Patient preference for method of receiving information
Patients most frequently selected a discussion with their nurse or physician (85%) and written information (67%) as their preferred methods for receiving information. Less preferred methods included the internet (29%), short video (12%), and receiving the information from another patient (8%).
Physician preference for communication aids
The physicians' preferred aids to communication were pamphlets (67%), followed by a website explaining key facts (44%), patient video (41%), and scripts for them to use (26%).
DISCUSSION
Molecular testing to inform treatment choices is now standard of care in several types of cancer. However, there are neither established communication guidelines for the information physicians should include during these discussions 14, 17, 50 nor patient-physician consensus on the most important information to discuss. [18] [19] [20] [21] [22] [23] [42] [43] [44] [45] [46] Therefore, it is vital to include current patients' voices and preferences in creating molecular testing guidelines. This study successfully identified patients' and physicians' preferences for molecular testing communication, patients' preferences for the method of receiving information, and physicians' preferences for communication aids.
The 2 most frequently chosen topics of information for both patients and physicians were the benefits of the test and how the test determines treatment, revealing a consensus for at least 2 crucial pieces of information to share. Patients' third choice-how their results may help family members determine their risk of cancer and other diseases (71%)-highlights the importance of physician-patient discussions of the differences between germline and somatic testing and what molecular testing can and cannot accurately reveal about a patient and a patient's family members.
14, 50 We therefore recommend that the differences between somatic and germline mutations be emphasized during molecular testing discussions in accordance with ASCO recommendations.
14 Patients' next preferred topic-how serious my disease is (68%)-demonstrates the importance of discussing the difficult topic of prognosis. 22, 23 In addition, the differences in physician and patient preferences for discussing IFs reflect the current literature, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] suggesting that, similar to potentially clinically significant IFs in genetic and fullexome testing, patients undergoing molecular testing also prefer disclosure of IFs. This finding expands the clinical settings in which IFs are of significant importance to patients, even if such findings are rare.
There was important consensus between patient and physician preferences about the most essential pieces of information to discuss during molecular testing conversations (Table 1). Twelve of these topics were those chosen by patients: the 1 additional topic added by physicians was cost. There were also 5 statistically significant differences (Table 5) . Physicians selected purpose (topic 1), limitations (topic 4), and cost (topic 5) with greater statistical frequency, whereas patients selected implications for family members (topic 8) and IFs (topic 10) with greater statistical frequency. In addition, uninformative results (topic 9) and explanation of biomarkers (topic 15) were only included above the second break point for patients (Table 5 ). All items that physicians chose more frequently than patients as important to discuss were in the foundational informed-consent domain (topics Original Article 1-5). In contrast, the items patients chose to discuss were mostly in the treatment and results domain (topics 6-10) (see Table 1 for distribution of domains). Therefore, we recommend emphasizing the latter domain-treatments and results-in molecular testing discussion guidelines to ensure physicians discuss topics of high importance to patients.
Limitations and Future Studies
Because this study was conducted using a convenience sample with a modest number of oncologists and health care settings, we cannot generalize these findings beyond our sites. The findings from our study could be driven by local practice patterns and preferences relevant to the catchment area of Winship Cancer Institute. Further studies in larger and diverse patient groups will be necessary to generalize our findings.
Future Research
A larger multi-institutional study assessing patient and provider informational preferences could expand on these data and further inform the creation of molecular testing guidelines. In addition, given the physician preference for pamphlets to communicate this information, the creation and testing of such pamphlets or flip charts, like those used by genetic counselors, could be fruitful.
Conclusions
The 12 topics chosen by patients should be discussed with the possible of addition of cost. These results can inform future guidelines and can contribute to effective communication regarding molecular testing.
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